Nova Scotia to implement DeltaWare's Medigent Drug Information System

MAXIMUS, Inc. (NYSE:MMS), a leading provider of government services worldwide, announced that its Canadian business unit DeltaWare Systems (DeltaWare) was awarded a contract with the Government of Nova Scotia for the implementation of its Medigent^® Drug Information System (DIS). DeltaWare is currently one of only three Canada Health Infoway-approved suppliers that offer a DIS conforming to Canadian clinical drug messaging standards.

Nova Scotia's DIS will manage the medication portion of a patient's health record. The system protects patients by linking all critical healthcare locations - from community pharmacies to hospitals - to a database that contains patient medication records for all residents of Nova Scotia. The system provides complete and up-to-date medication profiles and information for improved health planning, evaluation and research. It also includes a robust Drug Utilization Review that accesses, in real-time, a patient's entire medication profile and other attributes of a patient's clinical history, such as allergies and intolerances, medical conditions, and observations to detect and prevent potentially dangerous drug interactions. The Medigent DIS is just one of the modules that are part of DeltaWare's scalable Medigent Suite of health care solutions.

Through the new pan-Canadian messaging standards, the Medigent DIS will be seamlessly integrated with pharmacy Point-of-Service systems and physician electronic medical records. The implementation of Medigent DIS represents a significant step towards the creation of interoperable electronic health records (iEHRs) for the residents of Nova Scotia.

"Nova Scotia is the third province in Canada to implement DeltaWare's Medigent DIS," commented MAXIMUS CEO Richard Montoni. "As governments seek to drive efficiencies and quality of care improvements in their overall health delivery systems, Medigent will provide a critical link between pharmacies and physician records, helping health care professionals avoid dangerous drug interactions and duplications of therapy."

Source: MAXIMUS